All In Biotech

Drug Trial Radar · NCT01619865

Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors

Safety & Efficacy of 68Ga-DOTA-tyr3-Octreotide PET/CT in Diagnosis, Staging & Measurement of Response to Treatment in Patients With Somatostatin Receptor Positive Tumors: Comparison to Octreoscan Plus High-Resolution, Contrast Enhanced CT.

Last checked: Nov 20, 2026Latest source record: Jul 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

223

Actual

Start

Feb 21, 2012

Primary completion

Aug 27, 2017

Study completion Aug 27, 2017

Sponsor

Lead sponsor
Sue O'DorisioAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 14, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This protocol is designed to test the efficacy of 68Ga-DOTATOC PET/CT in diagnosis, staging, and measurement of response to treatment in patients with somatostatin receptor positive tumors. Goals are to 1) compare this unique PET/CT scan with the current standard of care which is a combination of Octreoscan SPECT (single photon emission tomography) plus a high resolution, contrast enhanced CT; 2) Determine the sensitivity of 68Ga-DOTATOC PET/CT in diagnosis of patients with suspected somatostatin receptor positive tumor; and 3) For those patients who have had recent treatment (e.g., surgery, chemotherapy, targeted therapy such as anti-angiogenics, kinase inhibitors, peptide receptor radiotherapy), this scan will be used to measure response to treatment. These studies will be obtained with the long term goal of submitting a New Drug Application (NDA) for FDA approval of 68Ga-DOTATOC PET/CT in adults and children.

Conditions

  • Neuroendocrine Tumors
  • Carcinoid Tumors
  • Neuroblastoma
  • Medulloblastoma

Interventions

  • 68Ga-DOTATOC PET/CTDrug

    1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To Measure Safety of 68Ga-DOTATOC Positron Emission Tomography (PET) by Measuring the Number of Adverse Events Related to the Investigational Radiopharmaceutical AgentTime frame: During PET scan and 24 hours post scan
  2. Number of Subjects With Adverse Events Related to the Use of the 68Ga-DOTATOCTime frame: Up to 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Iowa Health Care

    Iowa City, Iowa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.